Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 5/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | MAPT | P10636 | 5/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.50 |
| ▸ | POLB | P06746 | 4/20 | 0.50 |
| ▸ | RECQL | P46063 | 2/20 | 0.50 |
| ▸ | APEX1 | P27695 | 2/20 | 0.50 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.50 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.50 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.50 |
| ▸ | RPS6KB2 | Q9UBS0 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 2/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.46 |
| ▸ | ACACA | Q13085 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13065318 | 0.91 | HPGD (0.52) | HPGDKMT2AMAPTMEN1ALDH1A1 | |
| SCHEMBL16564292 | 0.89 | HPGD (0.50) | HPGDKMT2AMAPTMEN1ALDH1A1 | |
| SCHEMBL11626640 | 0.89 | HPGD (0.50) | HPGDKMT2AMAPTMEN1ALDH1A1 | |
| SCHEMBL6081236 | 0.89 | HPGD (0.50) | HPGDKMT2AMAPTMEN1ALDH1A1 | |
| SCHEMBL8437531 | 0.89 | HPGD (0.50) | HPGDKMT2AMAPTMEN1ALDH1A1 | |
| SCHEMBL9880895 | 0.89 | HPGD (0.50) | HPGDKMT2AMAPTMEN1ALDH1A1 | |
| SCHEMBL1247069 | 0.87 | HPGD (0.49) | HPGDKMT2AMAPTMEN1ALDH1A1 | |
| SCHEMBL16564107 | 0.87 | HPGD (0.49) | HPGDKMT2AMAPTMEN1ALDH1A1 | |
| SCHEMBL2127658 | 0.85 | RPS6KB2 (0.56) | HPGDKMT2AMAPTMEN1ALDH1A1 | |
| SCHEMBL16564192 | 0.85 | HPGD (0.47) | HPGDKMT2AMAPTMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108530243-B | Process for the manufacture of nitriles and their corresponding amines | 中国石化扬子石油化工有限公司 | 2022-05-27 | — | — | CN | claimed |
| CN-108546224-B | Process for the manufacture of nitriles and their corresponding amines | 中国石化扬子石油化工有限公司 | 2022-05-27 | — | — | CN | claimed |
| CN-108530244-B | Process for the manufacture of nitriles and their corresponding amines | 中国石化扬子石油化工有限公司 | 2022-02-11 | — | — | CN | claimed |
| CN-108530243-B | Process for the manufacture of nitriles and their corresponding amines | 中国石化扬子石油化工有限公司 | 2022-05-27 | — | — | CN | disclosed |
| CN-108546224-B | Process for the manufacture of nitriles and their corresponding amines | 中国石化扬子石油化工有限公司 | 2022-05-27 | — | — | CN | disclosed |
| CN-108530244-B | Process for the manufacture of nitriles and their corresponding amines | 中国石化扬子石油化工有限公司 | 2022-02-11 | — | — | CN | disclosed |
| US-10975099-B2 | Thiophene compounds for long-acting injectable compositions and related methods | ALKERMES PHARMA IRELAND LIMITED (IE) | 2021-04-13 | — | — | US | disclosed |
| US-10975099-B2 | Thiophene compounds for long-acting injectable compositions and related methods | ALKERMES PHARMA IRELAND LIMITED (IE) | 2021-04-13 | — | — | US | disclosed |
| US-20200325157-A1 | Novel Thiophene Compounds for Long-Acting Injectable Compositions and Related Methods | ALKERMES PHARMA IRELAND LIMITED (IE) | 2020-10-15 | — | — | US | disclosed |
| US-20200325157-A1 | Novel Thiophene Compounds for Long-Acting Injectable Compositions and Related Methods | ALKERMES PHARMA IRELAND LIMITED (IE) | 2020-10-15 | — | — | US | disclosed |
| EP-2236508-B1 | Reactive Heterocycle-Substituted 7-Hydroxycoumarins and Their Conjugates | BECTON DICKINSON CO (US) | 2015-08-26 | — | — | EP | disclosed |
| US-6740760-B2 | SUCH AS 1-((S)-3-MERCAPTO-2-METHYL-PROPIONYL)-(R)-PYRROL-IDINE-2-CARBOXYLIC ACID FOR TREATING DISEASES ASSOCIATED WITH AMYLOIDOSIS (ALZHEIMER'S DISEASE, DIABETES, AND FAMILIAL AMYLOID POLYNEUROPATHY) | HOFFMANN-LA ROCHE INC. | 2004-05-25 | — | — | US | disclosed |
| US-20030100770-A1 | Such as 1-((S)-3-mercapto-2-methyl-propionyl)-(R)-pyrrol-idine-2-carboxylic acid for treating diseases associated with amyloidosis (Alzheimer's disease, diabetes, and familial amyloid polyneuropathy) | PENTRAXIN THERAPEUTICS LTD. (GB) | 2003-05-29 | — | — | US | disclosed |
| US-6512001-B1 | To treat diseases associated with amyloidosis, such as Alzheimer's disease | HOFFMANN-LA ROCHE INC. | 2003-01-28 | — | — | US | disclosed |
| EP-0915088-B1 | D-Proline derivatives | HOFFMANN LA ROCHE (CH) | 2002-09-18 | — | — | EP | disclosed |
| US-6262089-B1 | USING THESE COMPOUNDS TO TREAT DISEASES ASSOCIATED WITH AMYLOIDOSIS, SUCH AS ALZHEIMER'S DISEASE, MATURITY ONSET DIABETES MELLITUS, FAMILIAL AMYLOID POLYNEUROPATHY, SCRAPIE, AND KREUZFELD-JACOB DISEASE. | HOFFMAN-LA ROCHE INC. | 2001-07-17 | — | — | US | disclosed |
| US-6103910-A | FOR TREATMENT OF DISEASES ASSOCIATED WITH AMYLOIDOSIS, SUCH AS ALZHEIMER'S DISEASE, DIABETES MELLITUS, FAMILIAL AMYLOID POLYNEUROPATHY, SCRAPIE, AND KREUZFELD-JACOB DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2000-08-15 | — | — | US | disclosed |
| CN-1217327-A | D-proline derivative | HOFFMANN LA ROCHE (CH) | 1999-05-26 | — | — | CN | disclosed |
| EP-0915088-A1 | D-Proline derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1999-05-12 | — | — | EP | disclosed |
| US-5536724-A | Antiinflammatory and antineoplastic 5-deazaaminopterins and 5,10-dideazaaminopterins | SRI INTERNATIONAL (US) | 1996-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100770-A1 | Such as 1-((S)-3-mercapto-2-methyl-propionyl)-(R)-pyrrol-idine-2-carboxylic acid for treating diseases associated with amyloidosis (Alzheimer's disease, diabetes, and familial amyloid polyneuropathy) | PSEN1, PSEN2, IAPP | HPGD 1894/4885KMT2A 2513/4885MAPT 23/4885 |
| US-20200325157-A1 | Novel Thiophene Compounds for Long-Acting Injectable Compositions and Related Methods | OPRK1, OPRM1, OPRD1 | HPGD 1060/4885KMT2A 2938/4885MAPT 495/4885 |
| US-10975099-B2 | Thiophene compounds for long-acting injectable compositions and related methods | OPRK1, OPRM1, OPRD1 | HPGD 684/4885KMT2A 2625/4885MAPT 474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.